FDA Determines Regulatory Review Period for OMONTYS Patent Extension

Summary

The Food and Drug Administration has officially confirmed the regulatory review period for OMONTYS, a human drug product, in accordance with federal regulations, following a patent extension application submitted to the U.S. Patent and Trademark Office.